The role of combined oral contraceptives in the management of acne and seborrhea

被引:12
作者
del Marmol, V
Teichmann, A
Gertsen, K
机构
[1] Free Univ Brussels, Erasme Hosp, Dept Dermatol, Brussels, Belgium
[2] Klinikum Aschaffenburg, Frauenklin, Aschaffenburg, Germany
[3] Organon Int BV, NL-5340 BH Oss, Netherlands
关键词
oral contraceptives; desogestrel; progestogens; acne; seborrhea; women; safety; acceptability;
D O I
10.1080/1362518042000221508
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Acne and seborrhea (or facial oiliness) are related androgenic skin disorders which affect a high proportion of women after menarche. They can have a negative effect on psychological well-being and social life. Androgens play an important role in the pathogenesis of acne through the stimulation of sebum secretion, increasing sebaceous gland size and possibly through follicular hyperkeratinization. Conversely, estrogens decrease sebum production by suppressing gonadotropin release and androgen production and increasing sex hormone binding globulin production. One of the treatment options for these conditions is hormonal therapy, especially for women who require contraception. The effect of combined oral contraceptives in androgenic skin disorders depends on their estrogen : progestogen balance and on the antiestrogenic activity of the progestogen component. Improved understanding of what women value about oral contraceptives suggests that the choice of product should be tailored as much as possible to the individual. Several combined oral contraceptives containing new-generation progestogens (e.g. desogestrel, gestodene) or progestational antiandrogens (e.g. cyproterone acetate, chlormadinone acetate) have demonstrated efficacy in the treatment of women with acne, although comparisons between trials are difficult because of differing endpoints. Seborrhea has been less well studied, but the few studies that are available show an improvement in women with this condition using combined oral contraceptives.
引用
收藏
页码:107 / 124
页数:18
相关论文
共 85 条
[71]   Cervical cancer and use of hormonal contraceptives: a systematic review [J].
Smith, JS ;
Green, J ;
Berrington de Gonzalez, A ;
Appleby, P ;
Peto, J ;
Plummer, M ;
Franceschi, S ;
Beral, V .
LANCET, 2003, 361 (9364) :1159-1167
[72]   ORAL-CONTRACEPTIVES AND NEOPLASIA OF THE OVARY [J].
STANFORD, JL .
CONTRACEPTION, 1991, 43 (06) :543-556
[73]   Update and future of hormonal therapy in acne [J].
Thiboutot, D ;
Chen, WC .
DERMATOLOGY, 2003, 206 (01) :57-67
[74]   Hormones and acne: Pathophysiology, clinical evaluation, and therapies [J].
Thiboutot, D .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2001, 20 (03) :144-153
[75]  
van Vloten Willem A, 2002, Cutis, V69, P2
[76]   Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate [J].
Vartiainen, M ;
de Gezelle, H ;
Broekmeulen, CJH .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2001, 6 (01) :46-53
[77]   ENDOMETRIAL AND OVARIAN-CANCER AND ORAL-CONTRACEPTIVES - FINDINGS IN A LARGE COHORT STUDY [J].
VESSEY, MP ;
PAINTER, R .
BRITISH JOURNAL OF CANCER, 1995, 71 (06) :1340-1342
[78]   EFFICACY ON HYPERANDROGENISM AND SAFETY OF A NEW ORAL-CONTRACEPTIVE BIPHASIC FORMULATION CONTAINING DESOGESTREL [J].
VOLPE, A ;
SILFERI, M ;
MAURI, A ;
DEIANA, P ;
ANGIONI, S ;
GRASSO, A ;
GENAZZANI, AR .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1994, 53 (03) :205-209
[79]   A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany [J].
Vree, ML ;
Schmidt, J .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2001, 6 (02) :108-114
[80]   Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception [J].
Wanichsetakul, P ;
Kamudhamas, A ;
Watanaruangkovit, P ;
Siripakarn, Y ;
Visutakul, P .
CONTRACEPTION, 2002, 65 (06) :407-410